About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNPhase 2NCT04433845

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with BP-II, current episode depressed, in improving depressive ...

Lead sponsor: Sheppard Pratt Health System•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Sheppard Pratt Health System

Collaborators

COMPASS Pathways

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Diagnosis of Type 2 Bipolar Disorder (BP-II) Depression

Exclusion Criteria

•Comorbidities

Related studies

RECRUITINGPhase 1

Psilocybin for Treatment-Resistant Depression in Autism

NCT06731621 · Treatment Resistant Depression, Autism Spectrum Disorder

University of Iowa Interventional Psychiatry Service Patient Registry

NCT04480918 · Treatment Resistant Depression, Major Depressive Episode, and more

RECRUITINGPhase 3

Biomarker-guided rTMS for Treatment Resistant Depression

NCT04041479 · Treatment Resistant Depression, Major Depressive Disorder

RECRUITINGPhase 2

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

NCT06524830 · Treatment Resistant Depression

A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.

NCT03320304 · Treatment Resistant Depression

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 25, 2022Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE2

Enrollment15

Start dateMar 2021

Last updatedOct 25, 2022

Condition

Treatment Resistant Depression

Locations shown

Sheppard Pratt

Baltimore, Maryland

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 25, 2022Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions